Sarah Kaplan writes for The Washington Post: “It looks to me like there are more hurdles being put in front of this drug than there have been on drugs addressing male dysfunction,” Terry O’Neill, president of the National Organization for Women, told The Washington Post after flibanserin was rejected a second time. “Obviously, everyone only wants drugs to get on the market if they are proven safe and effective. But we don’t want attitudes to get in the way of a good drug.”